488 related articles for article (PubMed ID: 17638918)
41. Activation of stress response gene SIRT1 by BCR-ABL promotes leukemogenesis.
Yuan H; Wang Z; Li L; Zhang H; Modi H; Horne D; Bhatia R; Chen W
Blood; 2012 Feb; 119(8):1904-14. PubMed ID: 22207735
[TBL] [Abstract][Full Text] [Related]
42. Bruton's tyrosine kinase is not essential for Bcr-Abl-mediated transformation of lymphoid or myeloid cells.
MacPartlin M; Smith AM; Druker BJ; Honigberg LA; Deininger MW
Leukemia; 2008 Jul; 22(7):1354-60. PubMed ID: 18548107
[TBL] [Abstract][Full Text] [Related]
43. Effect of imatinib mesylate on chronic myelogenous leukemia hematopoietic progenitor cells.
Holtz MS; Bhatia R
Leuk Lymphoma; 2004 Feb; 45(2):237-45. PubMed ID: 15101707
[TBL] [Abstract][Full Text] [Related]
44. Linkage of proliferative and maturational abnormalities in chronic myelogenous leukemia and relevance to treatment.
Clarkson B; Strife A
Leukemia; 1993 Nov; 7(11):1683-721. PubMed ID: 8231240
[TBL] [Abstract][Full Text] [Related]
45. c-kit ligand stimulates tyrosine phosphorylation of a similar pattern of phosphotyrosyl proteins in primary primitive normal hematopoietic progenitors that are constitutively phosphorylated in comparable primitive progenitors in chronic phase chronic myelogenous leukemia.
Wisniewski D; Strife A; Berman E; Clarkson B
Leukemia; 1996 Feb; 10(2):229-37. PubMed ID: 8637231
[TBL] [Abstract][Full Text] [Related]
46. Gene expression profiling of Philadelphia chromosome (Ph)-negative CD34+ hematopoietic stem and progenitor cells of patients with Ph-positive CML in major molecular remission during therapy with imatinib.
Neumann F; Teutsch N; Kliszewski S; Bork S; Steidl U; Brors B; Schimkus N; Roes N; Germing U; Hildebrandt B; Royer-Pokora B; Eils R; Gattermann N; Haas R; Kronenwett R
Leukemia; 2005 Mar; 19(3):458-60. PubMed ID: 15618956
[No Abstract] [Full Text] [Related]
47. Inhibition of small GTPase RalA regulates growth and arsenic-induced apoptosis in chronic myeloid leukemia (CML) cells.
Zhu X; Li Y; Luo X; Fei J
Cell Signal; 2012 Jun; 24(6):1134-40. PubMed ID: 22330069
[TBL] [Abstract][Full Text] [Related]
48. Growth autonomy and lineage switching in BCR-ABL-transduced human cord blood cells depend on different functional domains of BCR-ABL.
Chalandon Y; Jiang X; Loutet S; Eaves AC; Eaves CJ
Leukemia; 2004 May; 18(5):1006-12. PubMed ID: 15014528
[TBL] [Abstract][Full Text] [Related]
49. [The Philadelphia chromosome: from the gene to therapeutic methods].
Pérez-Losada J; González-Sarmiento R; Sánchez-García I
Sangre (Barc); 1998 Apr; 43(2):127-35. PubMed ID: 9656774
[No Abstract] [Full Text] [Related]
50. Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia.
Zhang X; Ren R
Blood; 1998 Nov; 92(10):3829-40. PubMed ID: 9808576
[TBL] [Abstract][Full Text] [Related]
51. Increased expression of fibroblast growth factor receptor 3 in CD34+ BCR-ABL+ cells from patients with chronic myeloid leukemia.
Dvorak P; Dvorakova D; Doubek M; Faitova J; Pacholikova J; Hampl A; Mayer J
Leukemia; 2003 Dec; 17(12):2418-25. PubMed ID: 14562121
[TBL] [Abstract][Full Text] [Related]
52. Bcr-Abl activates AURKA and AURKB in chronic myeloid leukemia cells via AKT signaling.
Yang J; Ikezoe T; Nishioka C; Udaka K; Yokoyama A
Int J Cancer; 2014 Mar; 134(5):1183-94. PubMed ID: 23934627
[TBL] [Abstract][Full Text] [Related]
53. The BCR/ABL transgene causes abnormal NK cell differentiation and can be found in circulating NK cells of advanced phase chronic myelogenous leukemia patients.
Nakajima H; Zhao R; Lund TC; Ward J; Dolan M; Hirsch B; Miller JS
J Immunol; 2002 Jan; 168(2):643-50. PubMed ID: 11777957
[TBL] [Abstract][Full Text] [Related]
54. Gene therapy for chronic myelogenous leukemia (CML): a retroviral vector that renders hematopoietic progenitors methotrexate-resistant and CML progenitors functionally normal and nontumorigenic in vivo.
Zhao RC; McIvor RS; Griffin JD; Verfaillie CM
Blood; 1997 Dec; 90(12):4687-98. PubMed ID: 9389683
[TBL] [Abstract][Full Text] [Related]
55. BCR-ABL promotes neutrophil differentiation in the chronic phase of chronic myeloid leukemia by downregulating c-Jun expression.
Kobayashi S; Kimura F; Ikeda T; Osawa Y; Torikai H; Kobayashi A; Sato K; Motoyoshi K
Leukemia; 2009 Sep; 23(9):1622-7. PubMed ID: 19357699
[TBL] [Abstract][Full Text] [Related]
56. Chronic myelogenous leukemia: molecular and cellular aspects.
Pasternak G; Hochhaus A; Schultheis B; Hehlmann R
J Cancer Res Clin Oncol; 1998; 124(12):643-60. PubMed ID: 9879825
[TBL] [Abstract][Full Text] [Related]
57. Proliferating status of peripheral blood progenitor cells from patients with BCR/ABL-positive chronic myelogenous leukemia.
Krämer A; Löffler H; Bergmann J; Hochhaus A; Hehlmann R
Leukemia; 2001 Jan; 15(1):62-8. PubMed ID: 11243401
[TBL] [Abstract][Full Text] [Related]
58. Tyrphostin AG957, a tyrosine kinase inhibitor with anti-BCR/ABL tyrosine kinase activity restores beta1 integrin-mediated adhesion and inhibitory signaling in chronic myelogenous leukemia hematopoietic progenitors.
Bhatia R; Munthe HA; Verfaillie CM
Leukemia; 1998 Nov; 12(11):1708-17. PubMed ID: 9823945
[TBL] [Abstract][Full Text] [Related]
59. Depression of oncogenecity by dephosphorylating and degrading BCR-ABL.
Gao M; Huang ZL; Tao K; Xiao Q; Wang X; Cao WX; Xu M; Hu J; Feng WL
Oncotarget; 2017 Jan; 8(2):3304-3314. PubMed ID: 27926512
[TBL] [Abstract][Full Text] [Related]
60. Hypoxia suppresses BCR/Abl and selects imatinib-insensitive progenitors within clonal CML populations.
Giuntoli S; Rovida E; Barbetti V; Cipolleschi MG; Olivotto M; Dello Sbarba P
Leukemia; 2006 Jul; 20(7):1291-3. PubMed ID: 16710305
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
